RenovoRx Inc (RNXT): Next-Year EPS Estimate 50.85%
As of 2026-06-04, RenovoRx Inc (RNXT) has a next-year EPS growth estimate of 50.85%.
On 2026-06-01, analyst consensus for RNXT's next-year EPS growth shifted from 53.04% to 50.85% — a negative change of 2.19 percentage points. The revised estimate has been sustained across 4 subsequent trading sessions. Current-year growth is projected at 7.81%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 50.85%
- EPS growth this year
- 7.81%
- EPS next quarter (est)
- -$0.07
- Last price
- $0.98
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 50.85% | 7.81% | -$0.07 | $0.98 |
| 2026-06-03 | 50.85% | 7.81% | -$0.07 | $0.91 |
| 2026-06-02 | 50.85% | 7.81% | -$0.07 | $0.91 |
| 2026-06-01 | 50.85% | 7.81% | -$0.07 | $0.92 |
| 2026-05-31 | 53.04% | 10.16% | -$0.07 | $0.91 |
| 2026-05-28 | 53.04% | 10.16% | -$0.07 | $0.99 |
| 2026-05-27 | 53.04% | 10.16% | -$0.07 | $0.93 |
| 2026-05-26 | 53.04% | 10.16% | -$0.07 | $0.92 |
| 2026-05-25 | 53.04% | 10.16% | -$0.07 | $0.88 |
| 2026-05-24 | 53.04% | 10.16% | -$0.07 | $0.88 |
| 2026-05-21 | 53.04% | 10.16% | -$0.07 | $0.88 |
| 2026-05-20 | 53.04% | 10.16% | -$0.07 | $0.81 |
| 2026-05-19 | 53.04% | 10.16% | -$0.07 | $0.81 |
| 2026-05-18 | 53.04% | 10.16% | -$0.07 | $0.78 |
| 2026-05-17 | 53.04% | 10.16% | -$0.07 | $0.82 |
| 2026-05-14 | 53.10% | 11.72% | -$0.08 | $0.86 |
| 2026-05-13 | 53.10% | 11.72% | -$0.08 | $0.87 |
| 2026-05-12 | 53.10% | 11.72% | -$0.08 | $0.87 |
| 2026-05-11 | 53.10% | 11.72% | -$0.08 | $0.85 |
| 2026-05-10 | 53.10% | 11.72% | -$0.08 | $0.86 |
| 2026-05-07 | 53.10% | 11.72% | -$0.08 | $0.88 |
| 2026-05-06 | 53.10% | 11.72% | -$0.08 | $0.89 |
| 2026-05-05 | 53.10% | 11.72% | -$0.08 | $0.93 |
| 2026-05-04 | 53.10% | 11.72% | -$0.08 | $0.89 |
| 2026-05-03 | 53.10% | 11.72% | -$0.08 | $0.88 |
| 2026-04-30 | 53.10% | 11.72% | -$0.08 | $0.85 |
| 2026-04-29 | 53.10% | 11.72% | -$0.08 | $0.83 |
| 2026-04-28 | 53.10% | 11.72% | -$0.08 | $0.84 |
| 2026-04-27 | 53.10% | 11.72% | -$0.08 | $0.87 |
| 2026-04-26 | 53.10% | 11.72% | -$0.08 | $0.86 |
Recent News
- RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa VasorumGlobeNewswire
- RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...GuruFocus.com
- RenovoRx Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Earnings To Watch: RenovoRx Inc (RNXT) Reports Q1 2026 ResultGuruFocus.com
- RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of EnrollmentGlobeNewswire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is RenovoRx Inc's next-year EPS growth estimate?▾
As of 2026-06-04, RenovoRx Inc (RNXT) has a next-year EPS growth estimate of 50.85%, based on analyst consensus.
When was the latest EPS estimate revision for RNXT?▾
The most recent revision occurred on 2026-06-01, when analysts adjusted the next-year EPS growth estimate from 53.04% to 50.85%.
What sector and industry does RenovoRx Inc belong to?▾
RenovoRx Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RNXT appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. RenovoRx Inc (RNXT) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports